Biotech Beach
Filter News
Found 76,859 articles
-
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
3/18/2024
Biora Therapeutics, Inc today announced it will report financial results and provide a corporate update for the fourth quarter and full year ended December 31, 2023.
-
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
3/18/2024
Exagen Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023.
-
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
3/18/2024
STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced that more than three million ICLs have been sold globally.
-
AliveGen Announces Successful Completion of Phase 1b Multiple-Ascending Dose Clinical Trial for ALG-801
3/18/2024
AliveGen USA Inc. is delighted to announce the successful completion of its Phase 1b multiple-ascending dose (MAD) clinical trial for ALG-801.
-
Immunis Chairman Dr. Hans Keirstead to Present Abundance360 Moonshot
3/18/2024
Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles.
-
San Diego Alzheimer's Partners Come Together
3/18/2024
The Alzheimer's Therapeutic Research Institute and over a half-dozen of San Diego's Alzheimer's partners invite the community to a free event on March 23, 2024.
-
Carlsmed Raises $52.5M in Series C Financing to Advance Personalized Spine Surgery
3/18/2024
Carlsmed, an AI-enabled personalized surgery Medtech company, announced today a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners.
-
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
3/18/2024
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium.
-
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
3/18/2024
Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2023.
-
PURE Bioscience Reports Fiscal Second Quarter 2024 Financial Results
3/18/2024
PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2024.
-
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
3/18/2024
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update.
-
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
3/17/2024
Aadi Bioscience, Inc. announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor had gynecologic origins experienced efficacy and safety consistent with the overall study population.
-
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
3/15/2024
Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2023 operating and financial results and reviewed recent business highlights.
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 15, 2024
3/15/2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and 5,461 restricted stock units (“RSUs”) to three new employees under Acadia’s 2023 Inducement Plan.
-
Navigate BioPharma Services, Inc. in Collaboration with Partners Validate Analytical Assay for Acute Myeloid Leukemia Measurable Residual Disease (AML-MRD) Assessment
3/15/2024
Navigate BioPharma Services, Inc. in Collaboration with Partners Validate Analytical Assay for Acute Myeloid Leukemia Measurable Residual Disease (AML-MRD) Assessment.
-
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
3/15/2024
ResMed, the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and other chronic diseases, announced the results of its 2024 Global Sleep Survey in conjunction with World Sleep Day, shedding light on the critical sleep challenges faced by people around the world.
-
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
3/15/2024
Ensysce Biosciences, Inc. today reported financial results for the fourth quarter and full year of 2023.
-
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
3/15/2024
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer.
-
PreludeDx™ Announces Novel Test for Predicting Radiation Therapy Benefit and Recurrence Risk in Early-Stage Invasive Breast Cancer Patients
3/14/2024
Prelude Corporation has unveiled data from an analysis of over 700 early-stage invasive breast cancer patients for AidaBreast.
-
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
3/14/2024
GRI Bio, Inc. today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,007,970 titled, "Prevention and Treatment of Inflammatory Conditions."